Erythromycin Delayed-Release Tablets 333mg from Japan
Enteric-coated delayed-release tablets with 333mg erythromycin base to protect gastric mucosa, for duodenal ulcer treatment in retail bottles. HTS 3004.20.0020 covers formulated antibiotic dosage forms regardless of release mechanism.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Pharmaceuticals: patented pharma from JP/EU/KR/CH/LI — 15% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Dissolution profile testing per USP; acid resistance certification
• DESI compliance for older antibiotics
• Avoid moisture during shipping